The JCVI will look again at the recommendation that people under 40 should be offered non-AstraZeneca jabs if it means that it could speed up the rollout, member Professor Adam Finn sayS, APA reports citing BBC.
Currently, most under 40s are being offered an alternative to the AZ vaccine due to a link with rare blood clots.
Prof Finn told Sky's Sophy Ridge On Sunday it was "on the agenda and if necessary that's something that could be done".
"When we expressed a preference for non-AstraZeneca vaccines for this age group it was done in a very provisional way on the basis of everything going absolutely right.
"And if the evidence shows that the risk benefit balance for people in their 30s is to be offered that vaccine then absolutely that recommendation will be changed.
"At the moment we don't think that's necessary, but it could well become a recommendation in the future."